Hormonal Regulation of Bone Metabolism in Postmenopausal Women

Menopause triggers a cascade of endocrine changes that profoundly alter skeletal homeostasis. The decline in ovarian oestrogen (E2) removes a critical inhibitor of bone resorption, tipping the balance towards osteoclast‐driven breakdown of mineralised matrix. Concurrent rises in follicle‐stimulating hormone (FSH) and luteinising hormone amplify osteoclast differentiation, while alterations in parathyroid hormone, vitamin D metabolism and thyroid‐stimulating hormone further modulate calcium handling. As osteoblast activity falters under reduced growth hormone and insulin‐like growth factor‐1 signalling, net bone loss accelerates. This imbalance underlies the high prevalence of osteoporosis and fragility fractures in postmenopausal women. Contemporary research seeks not only to refine oestrogen replacement strategies but also to identify non‐classical modulators of bone remodelling, including pituitary hormones and novel bioactive compounds, with the aim of restoring skeletal resilience without systemic adverse effects.

Research from Nature Portfolio

A systems‐level investigation has used transcriptomic profiling combined with network pharmacology to elucidate how a traditional herbal formulation mitigates ovarian‐insufficiency-related bone loss. By mapping differential gene expression in the hypothalamus and identifying active constituents that modulate gonadotropin‐releasing hormone and FSH pathways, this work highlights key molecular nodes—such as MAPK and calcium signalling—that may be leveraged to preserve bone density. Molecular docking studies further propose specific bioactives that bind core proteins implicated in osteoclast regulation, offering a template for targeted therapeutic development.

Hormonal Regulation of Bone Metabolism in Postmenopausal Women publication trend

The graph below shows the total number of articles in hormonal regulation of bone metabolism in postmenopausal women across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoclast: A bone‐resorbing cell that degrades mineral and organic matrix during remodelling.

Osteoblast: A bone‐forming cell responsible for synthesising collagen and facilitating mineralisation.

Follicle‐stimulating hormone (FSH): A pituitary gonadotropin that rises after menopause and can enhance osteoclastogenesis.

Oestrogen (E2): The primary female sex hormone that inhibits bone resorption and supports osteoblast survival.

Bone remodelling: The coupled process of bone resorption by osteoclasts and formation by osteoblasts.

Receptor activator of nuclear factor κB ligand (RANKL): A key osteoclastogenic cytokine that binds RANK on precursor cells to drive their maturation.

References

1. Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly. Journal of Clinical Medicine (2019).
2. FSH and TSH in the Regulation of Bone Mass: The Pituitary/Immune/Bone Axis. Journal of Immunology Research (2013).
3. Bone Mineral Density in Different Menopause Stages is Associated with Follicle Stimulating Hormone Levels in Healthy Women. International Journal of Environmental Research and Public Health (2021).
4. Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation. PLOS ONE (2015).
5. To investigate the mechanism of Yiwei Decoction in the treatment of premature ovarian insufficiency-related osteoporosis using transcriptomics, network pharmacology and molecular docking techniques. Scientific Reports (2023).